Naslov
The results of the international clinical study VICTORY: efficacy and safety of antihypertensive monotherapy with valsartan (Valsacor) and its fixed combination with hydrochlrothiazide (Valsacor H) in routine clinical practice in patients with grade 1 and grade 2 hypertension

Autori
Chazova E, Irina ; Martynyk V, Tamila ; Accetto, Rok ; Sirenko, Yuriy ; Vincelj, Josip ; Widimsky Jr, Jiri ; Barbič Žagar, Breda et al.

Izvornik
Systemic Hypertension (2075-082X) 14 (2017), 2; 80-89

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Hypertension ; Combined antihypertensive therapy ; Valsartan ; Hydrochlorothiazide
(hypertension ; combined antihypertensive therapy ; valsartan ; hydrochlorothiazide)

Sažetak
The VICTORY study aimed to evaluate effectiveness and safety of monotherapy with valsartan (Valsacor) and its combination with hydrochlorothyazide (Valsacor H) in clinical practice in patients with stage 1 and stage 2 hypertension. In the prospective, randomized, open-label, international multicentre study involved 356 patients with grade 1 and grade 2 hypertension from 5 countries, including 130 patients from Russia. In Russia the study was conducted in 7 cities, in 8 clinical centers. The patients, who were receiving antihypertensive therapy at the moment of screening, underwent a 7 days wash-out period. The starter dose of valsartan (Valsacor KRKA, Slovenia) was 80 mg (expect for Russia where 160 mg of Valsacor were given at the first visit, what did not influence the study results). After 4 weeks of treatment in case of blood pressure (BP)>140/90 or 130/80 mmHg the dose was increased to 160 mg (in Russia-to 320 mg) or combined therapy with Valsacor H (KRKA, Slovenia) was prescibed. In 4 weeks the dose valsartan was increased to 320 mg or 160/12.5 mg in case of previous dose insufficiency. Data on 365 patients, 196 (54.0%) female and 169 (46.0%) male aged 54.6+/-12.0 years were analyzed. The study demonstrated high effectiveness and good tolerability of valsartan and its combination with HCTZ in patients with stage 1 and stage 2 hypertension. At the 16th week of treatment 90.6% reached target BP levels: 98% in the valsartan monotherapy group and 84% in the combination therapy with valsartan and HCTZ group. The therapeutic effect was estimated as good and very good in 96% of patients. There were no case of severe adverse events in the study. The most frequent adverse effects were headache (1.9%), dizziness (1.6%) and weakness (1.6%).

Izvorni jezik
Rus

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA